Northwest Biotherapeutics, Inc.
21720 23rd Drive SE
Suite 100
Bothell
Washington
98021
United States
Tel: 425-608-3000-or-877-606-9246-Toll-Free
Fax: 425-608-3026
Website: http://www.nwbio.com
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers.YEAR FOUNDED:
March 18, 1996
LEADERSHIP:
Founder: Alton Boynton
CEO: Hua Bai
CEO: Linda Powers
CTO: Marnix Bosch
CSO (Scientific): Alton Boynton
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW NORTHWEST BIOTHERAPEUTICS:
Tweets by Northwest Biotherapeutics
268 articles about Northwest Biotherapeutics, Inc.
-
Northwest Biotherapeutics Announces Appointment of Chief Financial Officer
10/2/2007
-
Northwest Biotherapeutics Disputes Patent Infringement Claims
8/1/2007
-
Northwest Biotherapeutics Responds to Media Reports
7/16/2007
-
Northwest Biotherapeutics Announces Effectiveness of Reverse Stock Split
6/28/2007
-
Northwest Biotherapeutics Closes Its Placement of Shares With Foreign Institutional Investors
6/22/2007
-
Northwest Biotherapeutics Announces Effectiveness of Reverse Stock Split
6/22/2007
-
Northwest Biotherapeutics Prices Its Intended Placement of Shares with Foreign Institutional Investors
6/18/2007
-
Northwest Biotherapeutics Initiates Its Intended Placement of Shares With Foreign Institutional Investors
6/4/2007
-
Northwest Biotherapeutics Intends to Place Shares With Foreign Institutional Investors
5/21/2007
-
Northwest Biotherapeutics Files for Authorization for Use of DCVax(R)-Brain for Commercialization in Switzerland
4/17/2007
-
Northwest Biotherapeutics Appoints Chief Financial Officer
3/8/2007
-
Northwest Biotherapeutics Adds University of California, Los Angeles (UCLA) as a Site to Its Pivotal Phase II Brain Cancer Trial
3/7/2007
-
First Patients Undergo Surgery In Northwest Biotherapeutics' Phase II Brain Cancer Trial
2/13/2007
-
Northwest Biotherapeutics Receives Institutional Review Board Approval To Accrue Patients In Phase II Brain Cancer Trial
11/28/2006
-
Northwest Biotherapeutics Discusses Results From Clinical Trials In Brain Cancer At Two Conferences
10/30/2006
-
Northwest Biotherapeutics To Present At The 21st Annual Meeting Of The International Society For Biological Therapy Of Cancer
10/26/2006
-
Northwest Biotherapeutics To Present At The CE Unterberg, Towbin Life Sciences Conference
10/23/2006
-
Northwest Biotherapeutics Updates Brain Cancer Clinical Data
8/28/2006
-
Northwest Biotherapeutics To Present Update On Brain Cancer Clinical Data At The Cambridge Healthtech Institute's Cancer Immunotherapeutics And Vaccines Conference
8/21/2006
-
Northwest Biotherapeutics To Present Data On CXCR4 At The Cambridge Healthtech Institute's Targeted Cancer Therapies Conference
8/17/2006